8-K: Dermata Therapeutics Announces Positive Topline Results from Phase 3 Acne Trial for XYNGARI

Dermata Therapeutics' XYNGARI met all primary endpoints in its first pivotal Phase 3 trial for moderate-to-severe acne, showing statistically significant improvement compared to placebo.

Summary

• Dermata Therapeutics announced positive topline results from its Phase 3 STAR-1 trial of XYNGARI for moderate-to-severe acne.
• The trial met all primary endpoints, demonstrating a statistically significant difference compared to placebo after 12 weeks of once-weekly treatment.
• The study enrolled 520 patients aged 9 years and older in the United States and Latin America.
• XYNGARI appeared safe and well-tolerated, with minimal treatment-related adverse events and no serious adverse events attributed to treatment.
• The company plans to initiate the second Phase 3 STAR-2 trial in the second half of 2025, followed by an open-label extension study.
• Positive results from the Phase 3 program are expected to support a new drug application with the FDA.
• In the trial, 29.4% of patients treated with XYNGARI achieved a 2-point reduction on the IGA scale and a score of 0 or 1, compared to 15.2% in the placebo group (p < 0.001).
• The mean change from baseline in inflammatory lesion count was -16.8 for XYNGARI and -13.1 for placebo (p < 0.001).
• The mean change from baseline in non-inflammatory lesion count was -17.3 for XYNGARI and -12.4 for placebo (p < 0.001).

Sentiment

Score: 8

Explanation: The document presents highly positive results from a Phase 3 trial, suggesting a promising future for the company's lead product candidate. The management's comments are enthusiastic, and the potential for a novel treatment in a large market contributes to a strong positive sentiment.

Positives

• XYNGARI demonstrated statistically significant improvement in acne compared to placebo in the Phase 3 STAR-1 trial.
• XYNGARI appeared to be safe and well-tolerated by patients.
• The trial met all primary endpoints.
• XYNGARI is a novel, once-weekly topical treatment, potentially improving patient compliance compared to daily treatments.
• The company plans to initiate the second Phase 3 STAR-2 trial in the second half of 2025.

Risks

• The success of the Phase 3 program depends on the positive results of the STAR-2 trial.
• Regulatory approval from the FDA is not guaranteed.
• The company's forward-looking statements are subject to risks and uncertainties inherent in drug development, approval, and commercialization.
• Past results of clinical trials may not be indicative of future trial results.

Future Outlook

The company plans to initiate the second Phase 3 STAR-2 trial in the second half of 2025, followed by an open-label extension study, with the goal of submitting a new drug application to the FDA.

Management Comments

• 'I believe having a once-weekly, topical product with a strong efficacy and safety profile, like XYNGARI, would be a great addition to a dermatologists arsenal for treating acne,' commented Dr. Sunil Dhawan, MD, FAAD, FACP, clinical investigator at the Center for Dermatology Clinical Research, Inc.
• Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata, stated that the company is incredibly excited about the Phase 3 clinical trial results for XYNGARI and believes they reinforce its potential as a unique acne treatment.
• Mr. Proehl added that the company is eager to advance discussions with potential partners interested in securing future rights to XYNGARI.
• Christopher Nardo, Ph.D., Chief Development Officer of Dermata, stated that the clinical response observed in the XYNGARI Phase 3 STAR-1 trial gives the company confidence that XYNGARI, if approved, could alter the current treatment paradigm in acne.

Industry Context

The announcement addresses the large acne treatment market, with over 30 million patients seeking treatment in the U.S. each year, and highlights the potential for XYNGARI as a novel, once-weekly topical treatment option.

Comparison to Industry Standards

• The press release mentions that all FDA approved topical acne products are required to be applied at least once or twice a day.
• XYNGARI's once-weekly application could offer a significant advantage in patient compliance compared to existing treatments like benzoyl peroxide, retinoids, and topical antibiotics.
• Companies like Galderma (Epiduo), Bausch Health (Duobrii), and others offer topical acne treatments, but none currently offer a once-weekly application.

Stakeholder Impact

• Positive results could lead to increased shareholder value.
• Successful commercialization of XYNGARI could provide a new treatment option for acne patients.
• Potential partnerships could benefit the company's financial position and future growth.

Next Steps

• Initiate the second Phase 3 STAR-2 trial in the second half of 2025.
• Conduct an open-label extension study following the STAR-2 trial.
• Advance discussions with potential partners interested in securing future rights to XYNGARI.
• Prepare for a potential new drug application with the FDA based on the Phase 3 program results.

Key Dates

Keywords

XYNGARI, acne, Phase 3 trial, Dermata Therapeutics, topical treatment, STAR-1, STAR-2, FDA, clinical trial, dermatology